New York, NY -- (SBWIRE) -- 01/13/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Celsion Corporation (NASDAQ:CLSN), Hemispherx BioPharma, Inc (NYSEMKT:HEB), Kingold Jewelry Inc (NASDAQ:KGJI), New Residential Investment Corp (NYSE:NRZ)
Celsion Corporation (NASDAQ:CLSN) showed a volume of 1.20 million shares by the end of last trade whereas the average volume of the stock remained 417,328.00 shares. The stock opened the session at $4.36 but then moved to $4.57. At that price, the stock showed a positive performance of 12.84%. Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. As of December 31, 2011, the Company's product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer. ThermoDox is a liposomal encapsulation of doxorubicin,
Will CLSN Continue To Move Higher? Find Out Here
Hemispherx BioPharma, Inc (NYSEMKT:HEB) opened the session at $0.29 and closed the session at $0.280. The stock showed a positive performance of 1.45% in previous trading session. Traded with volume of 1.20 million shares in the prior session and the average volume of the stock remained 2.11 million shares. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development.
For How Long HEB will fight for Profitability? Read This Trend Analysis report
Kingold Jewelry Inc (NASDAQ:KGJI) opened the session at $1.80 and closed the session at $1.85. The stock showed a positive performance of 4.52% in previous trading session. Traded with volume of 1.20 million shares in the prior session and the average volume of the stock remained 169,752.00 shares. The beta of the stock remained -0.95. Kingold Jewelry, Inc. (Kingold) is a designer and manufacturer of 24 Karat gold jewelry and Chinese ornaments. The Company is also engaged in developing, promoting, and selling a range of products to the jewelry market across the People’s Republic of China. The Company offers a range of in-house designed products, including, but not limited to, gold necklaces, rings, earrings, bracelets and pendants. As of December 31, 2011, the Company produced approximately 30 tons of 24 Karat gold products.
Why Should Investors Buy KGJI After The Recent Gain? Just Go Here and Find Out
New Residential Investment Corp (NYSE:NRZ) the stock advanced 1.56% and finished the session at $6.53. Traded with volume of 1.20 million shares in the prior session and the average volume of the stock remained 2.01 million shares. New Residential Investment Corp., incorporated on September 26, 2013, is a real estate investment trust. The Company focuses on investing in, and actively managing, investments related to residential real estate. The Company is managed by an affiliate of Fortress Investment Group LLC, a global investment management. The Company primarily target investments in excess mortgage servicing rights, residential mortgage backed securities, residential mortgage loans and other related investments.
Will NRZ Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)